Published • loading... • Updated
Efgartigimod Shows Promise in Immune Checkpoint Inhibitor-Related Myasthenia Gravis–Myositis Overlap Syndrome
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Efgartigimod Shows Promise in Immune Checkpoint Inhibitor-Related Myasthenia Gravis–Myositis Overlap Syndrome
A newly reported case from Nanchang University suggests that efgartigimod, a neonatal Fc receptor (FcRn) blocker approved for generalized myasthenia gravis, may offer a promising treatment option for patients who develop immune checkpoint inhibitor (ICI)-related myasthenia gravis (MG)-myositis overlap syndrome, a rare but potentially serious complication of cancer immunotherapy. Rare Neurological Toxicity of Immunotherapy Immune […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
